AstraZeneca makes progress with two breast cancer treatments

29th Apr 2024 07:24

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more

London close: Stocks finish mixed as US GDP growth slows

25th Apr 2024 15:14

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more

AstraZeneca blows past analysts' estimates for Q1

25th Apr 2024 08:38

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more

London close: Stocks finish lower as ECB stands pat

11th Apr 2024 15:56

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more

AstraZeneca to hike 2024 dividend by 7%

11th Apr 2024 07:20

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more

AstraZeneca's Enhurtu cancer gets US green light for adult patients

8th Apr 2024 07:02

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more

AstraZeneca announces positive lung cancer treatment trial results

5th Apr 2024 07:23

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more

London close: Stocks turn red on return from Easter break

2nd Apr 2024 15:22

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more

US FDA gives green light for use of AstraZeneca's Voydeva

2nd Apr 2024 07:08

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more

AstraZeneca gets FDA approval for Ultomiris treatment

25th Mar 2024 07:23

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more

AstraZeneca to buy US-listed Fusion Phrama for $2bn

19th Mar 2024 07:05

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

14th Mar 2024 07:16

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more

AstraZeneca's chemo replacement treatment moves closer to EU approval

4th Mar 2024 07:18

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more

AstraZeneca's blood-disorder drug recommended for EU approval

26th Feb 2024 07:22

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more

AstraZeneca acquires US-based biopharmaceutical company

20th Feb 2024 10:29

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more